Howard L Li

6PUBLICATIONS
49CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsComputational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|Apr 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma.

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Apr 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.

Chester Kao, Soren Charmsaz, Hua-Ling Tsai

|Mar 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.

Mari Nakazawa, Soren Charmsaz, Elsa Hallab

|Jun 10, 2021
Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor.

Eli J Cornblath, Howard L Li, Lakshmi Changolkar

Pageof 1

Frequent Collaborators

5 joint publications

Christopher Thoburn

5 joint publications

G Scott Chandler

5 joint publications

Won Jin Ho

4 joint publications

Marina Barretti